Chronic myeloid leukaemia News and Research

RSS

Long-term dasatinib findings support first-line use in CML

Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase-chronic myeloid leukaemia.

15 Jun 2016

$Allogeneic HSCT offers good survival for select TKI-refractory CML patients$

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests.

18 May 2016

Real-world CML management in line with ELN guidelines

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study.

18 May 2016

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.

18 May 2016

CML treatment-free remission criteria outlined

Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy.

18 May 2016

BCR-ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers.

21 Apr 2016

Bosutinib shows 'low' vascular, cardiac event risk profile

Third-generation tyrosine kinase inhibitor study findings suggest that bosutinib is associated with a low risk of vascular and cardiac events in patients undergoing first-line or subsequent treatment for chronic myeloid leukaemia.

21 Apr 2016

Imatinib-related symptom burden linked to adherence in Indian CML patients

Research shows low adherence to imatinib in Indian patients with chronic myeloid leukaemia, with an association between nonadherence and worse symptom burden related to treatment.

21 Apr 2016

Frontline nilotinib supported for newly diagnosed CP-CML

Long-term results from the ENESTnd trial indicate a favourable risk-benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase-chronic myeloid leukaemia diagnosis.

21 Apr 2016

Pre-TKI cytokine profiling predicts CP-CML outcome

Measuring levels of transforming growth factor-α and interleukin-6 may help identify patients with newly diagnosed chronic phase-chronic myeloid leukaemia at risk of a poor outcome from tyrosine kinase inhibitor therapy, research suggests.

20 Apr 2016

Additional chromosomal abnormalities prognostic for CML

Additional chromosomal abnormalities can be used to create two prognostic groups of patients with chronic myeloid leukaemia, suggests research published in Blood.

20 Apr 2016

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate.

17 Mar 2016

Vascular events in CML may not be linked to TKI therapy

The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest.

17 Mar 2016

Real-life data show feasibility of imatinib discontinuation in CML

Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment.

17 Mar 2016

Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

A meta-analysis highlights the significantly increased risk of vascular occlusive events in patients with chronic myeloid leukaemia using some new-generation BCR-ABL tyrosine kinase inhibitors compared with use of imatinib.

17 Feb 2016

Allo-HSCT Non-Relapse Related Mortality Reduction Revealed

A reduction in the risks of infection- and organ failure-related death has driven an improvement in non-relapse mortality among recipients of allogeneic haematopoietic stem cell transplantation, Japanese research suggests.

17 Feb 2016

Mtss1 'tumour suppressor' for CML

The metastasis suppressor 1 protein acts a tumour suppressor in chronic myeloid leukaemia stem cells, reveals research published in Leukemia.

17 Feb 2016

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients.

22 Jan 2016

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia.

22 Jan 2016

BCR–ABL transcript type linked to TKI response, outcomes

The type of BCR–ABL transcript could have an impact on tyrosine kinase inhibitor choice in patients with chronic myeloid leukaemia , according to research published in Blood.

22 Jan 2016